Early this year, Olaparib was approved for adjuvant treatment of BRCA-mutated HER-2 negative early breast cancer patients who have received local treatment and neoadjuvant or adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.